Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the randomised control trial study report entitled Cost utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data, published in June 2022, what assessment he has made of the potential implications for his policies of the findings of that study on the cost utility of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in men with newly diagnosed high risk non metastatic prostate cancer.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England considered abiraterone as an off-label treatment for hormone sensitive, non-metastatic prostate cancer through its clinical policy development process in 2024/25. Through this process, NHS England confirmed that there was sufficient supporting evidence to support the routine commissioning of abiraterone in this indication, and it was ranked in the highest priority level. However, at this point in time, it has not been possible to identify the necessary recurrent headroom in revenue budgets to support the funding of any treatments under consideration. This position is being kept under review.
NHS England examined papers from the STAMPEDE trial, including Cost utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data, as part of the review of evidence for the policy proposition.